Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250614 · ClinicalTrials.gov registry record · Phase 3
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 452
- Enrollment target
NCT00250614 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 452 participants.
The verdict
NCT00250614, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 452 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
Interventions
- DRUG Saredutant succinate (SR48968C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250614
The ClinicalTrials.gov registry entry for NCT00250614 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saredutant succinate (SR48968C) is the first listed.
NCT00250614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250614 about?
NCT00250614 is a clinical study titled "An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression". The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the sa...
What is the current status of trial NCT00250614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 452 participants. The study started on 2005-04. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00250614?
The interventions under investigation include: Saredutant succinate (SR48968C) (DRUG).
Who is sponsoring clinical trial NCT00250614?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.